Carbimazole

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Breast Feeding; Lactation; Milk, Human; Antithyroid Agents; Thionamides

Thyroid hormones and antithyroid medicines

148.0 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID9022736]

143.69 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

134.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Danger

H302 (18.6%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P318, P319, P321, P330, P333+P317, P337+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

H360D: May damage the unborn child [Danger Reproductive toxicity]

Acute Tox. 4 (18.6%)

Reproductive toxicity - category 1B

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

CARBIMAZOLE

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

H - Systemic hormonal preparations, excl. sex hormones and insulins

QH - Systemic hormonal preparations, excl. sex hormones and insulin

Carbimazole is an aitithyroid agent that decreases the uptake and concentration of inorganic iodine by thyroid, it also reduces the formation of di-iodotyrosine and thyroxine. Once converted to its active form of methimazole, it prevents the thyroid peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4.